Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Albumin-Bound Paclitaxel × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 65 Pancreatic Neoplasms 47 Carcinoma, Non-Small-Cell Lung 28 Triple Negative Breast Neoplasms 24 Neoplasm Metastasis 14 Squamous Cell Carcinoma of Head and Neck 13 Ovarian Neoplasms 11 Lung Neoplasms 10 Esophageal Neoplasms 10 Neoplasms 9 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Melanoma 7 Uterine Cervical Neoplasms 6 Head and Neck Neoplasms 6 Cholangiocarcinoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Fallopian Tube Neoplasms 5 Urinary Bladder Neoplasms 4 Pancreatic Adenocarcinoma 4 Inflammatory Breast Neoplasms 4 Advanced Pancreatic Cancer 4 Sarcoma 3 Colorectal Neoplasms 3 Carcinoma, Transitional Cell 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms, Male 3 Adenocarcinoma 3 Uveal Melanoma 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡